scout
|Articles|July 1, 2008

Oncology NEWS International

  • Oncology NEWS International Vol 17 No 7
  • Volume 17
  • Issue 7

ThromboGenics and BioInvent Announce Alliance with Roche

UVEN, Belgium-ThromboGenics NV and BioInvent International AB (Lund, Sweden) have entered into a license agreement with Roche for their jointly developed anticancer agent TB-403, a novel monoclonal antibody that blocks PIGF, one of the growth factors responsible for angiogenesis.

UVEN, Belgium-ThromboGenics NV and BioInvent International AB (Lund, Sweden) have entered into a license agreement with Roche for their jointly developed anticancer agent TB-403, a novel monoclonal antibody that blocks PIGF, one of the growth factors responsible for angiogenesis.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.


Latest CME